344 related articles for article (PubMed ID: 23887059)
1. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
[TBL] [Abstract][Full Text] [Related]
3. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
[TBL] [Abstract][Full Text] [Related]
5. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A; Mueller C; Nowak RM; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng LL; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Hartmann O; Morgenthaler NG; Anker SD
J Am Coll Cardiol; 2011 Aug; 58(10):1057-67. PubMed ID: 21867843
[TBL] [Abstract][Full Text] [Related]
6. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Funke-Kaiser A; Mann K; Colquhoun D; Zeller T; Hunt D; Simes J; Sullivan D; Sydow K; West M; White H; Blankenberg S; Tonkin AM;
Int J Cardiol; 2014 Mar; 172(2):411-8. PubMed ID: 24508492
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients.
Adlbrecht C; Hülsmann M; Strunk G; Berger R; Mörtl D; Struck J; Morgenthaler NG; Bergmann A; Jakowitsch J; Maurer G; Lang IM; Pacher R
Eur J Heart Fail; 2009 Apr; 11(4):361-6. PubMed ID: 19190023
[TBL] [Abstract][Full Text] [Related]
8. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528
[TBL] [Abstract][Full Text] [Related]
9. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
[TBL] [Abstract][Full Text] [Related]
11. Mid-regional pro-adrenomedullin: an indicator of the failing Fontan circuit in patients with univentricular hearts?
Kaiser R; Abdul-Khaliq H; Wilkens H; Herrmann E; Raedle-Hurst TM
Eur J Heart Fail; 2014 Oct; 16(10):1082-8. PubMed ID: 25201135
[TBL] [Abstract][Full Text] [Related]
12. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
[TBL] [Abstract][Full Text] [Related]
13. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
[TBL] [Abstract][Full Text] [Related]
14. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population.
Brouwers FP; de Boer RA; van der Harst P; Struck J; de Jong PE; de Zeeuw D; Gans RO; Gansevoort RT; Hillege HL; van Gilst WH; Bakker SJ
Heart; 2012 Sep; 98(18):1348-53. PubMed ID: 22821276
[TBL] [Abstract][Full Text] [Related]
15. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
16. Cardiac biomarkers, mortality, and post-traumatic stress disorder in military veterans.
Xue Y; Taub PR; Iqbal N; Fard A; Wentworth B; Redwine L; Clopton P; Stein M; Maisel A
Am J Cardiol; 2012 Apr; 109(8):1215-8. PubMed ID: 22305506
[TBL] [Abstract][Full Text] [Related]
17. The influence of diabetes mellitus on midregional proadrenomedullin concentrations and prognostic value in heart failure outpatients.
Holmager P; Schou M; Egstrup M; Gustafsson I; Goetze JP; Gustafsson F; Klausen TW; Faber J; Kistorp C
J Card Fail; 2015 Mar; 21(3):250-7. PubMed ID: 25528198
[TBL] [Abstract][Full Text] [Related]
18. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
[TBL] [Abstract][Full Text] [Related]
19. Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community.
Eggers KM; Venge P; Lindahl B; Lind L
Int J Cardiol; 2013 Oct; 168(4):3537-42. PubMed ID: 23722054
[TBL] [Abstract][Full Text] [Related]
20. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
